← Leaderboards
Ana Maria Moreno
Navega Therapeutics, Inc.
$4,025,516
Attributed
$8,051,032
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2019–24$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,051,032 · 6
By mechanism
U44$4,279,361 · 1
R44$2,183,954 · 1
R43$1,187,717 · 3
SB1$400,000 · 1
Top collaborators
- Fernando Aleman Guillen14 shared
Most similar at Navega Therapeutics, Inc.
Same institution · by research overlap
- Fernando Aleman Guillen$4,025,516
- Yanmei Qi$297,327
Others in their field
Other Emerging Leaders on “Sodium Channel”
- John Cureton Hunter · Siteone Therapeutics, Inc.$6,388,430
- Ingo Helbig · Children'S Hosp Of Philadelphia$4,401,179
- Zhaozhu Qiu · Johns Hopkins University$4,356,661
- Fernando Aleman Guillen · Navega Therapeutics, Inc.$4,025,516
- Yang Yang · Purdue University$3,921,619
- David S Park · New York University School Of Medicine$3,390,000
Research focus
Sodium ChannelPainGene TherapyOpioidProteinsSide EffectPain ManagementAddictionDesignChronic PainRepressionSpecificityGenomeAlternative TreatmentGuide RnaAffectCongenital Pain InsensitivityVariantPain ReliefCrispr/Cas TechnologyInnovationDependovirusEpigenomeMutation
Grant awards (14)
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$1,528,057
U44 · FY2024 · NS
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$98,701
U44 · FY2024 · NS
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$74,701
U44 · FY2024 · NS
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$1,149,467
U44 · FY2023 · NS
Advancing precision pain medicines to the clinic$400,000
SB1 · FY2023 · NS · contact PI
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$1,283,183
R44 · FY2022 · CA
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$730,264
U44 · FY2022 · NS
Supplement to Promote Diversity, Inclusion, and Career Development of a Female Scientist$134,086
R44 · FY2022 · CA
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$766,685
R44 · FY2021 · CA
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$698,171
U44 · FY2021 · NS
Optimization of a Gene Therapy for Chronic Pain in Human DRGs$275,377
R43 · FY2021 · NS · contact PI
Supplement to Promote Diversity and Inclusion, Female Scientist$95,050
R43 · FY2020 · NS · contact PI
Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain$529,006
R43 · FY2019 · NS · contact PI
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$288,284
R43 · FY2019 · CA